China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
000999
Clasificación en acciones
#2914
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent... China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of medicinal products. Its operations span both the People's Republic of China and international markets, additionally providing various health-related services. The company's extensive product line includes a wide range of over-the-counter (OTC) medications addressing common conditions such as colds, skin issues, gastrointestinal complaints, coughs, and needs in orthopedics and pediatrics. It also provides prescription drugs, with a focus on areas like traditional Chinese medicine, oncology, cardiovascular and cerebrovascular health, digestive system disorders, orthopedics, and pediatrics. Further offerings comprise Chinese medicine injections, specialized formula granules, and anti-infective agents. These products are often marketed under popular brand families, notably 999 family medicine, Sanjiuweitai series, 999 Ganmaoling series, and 999 dermatitis series. Founded in 1999 and headquartered in Shenzhen, PRC, the company initially operated as Sanjiu Pharmaceutical Co., Ltd. before rebranding to its current name in February 2010. It functions as a subsidiary under the umbrella of China Resources (Holdings) Co., Ltd.
Precio por acción
$3.74
Capitalización bursátil
$6.23B
Cambio (1 día)
-2.11%
Cambio (1 año)
-8.54%
País
CN
Comercio China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)
Categoría
Healthcare
Ratio P/E de China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)
Ratio P/E al October 2026 TTM: 12.63
Según los últimos informes financieros y el precio de las acciones de China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., el P/E actual (TTM) de la empresa es 12.63. Al final de 2024, la empresa tenía un P/E de 16.86.
Historial del ratio P/E de China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. desde 2001 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 12.63 | -8.64% |
| 2025 | 13.82 | -18.06% |
| 2024 | 16.86 | -6.37% |
| 2023 | 18.01 | -4.60% |
| 2022 | 18.88 | 15.77% |
| 2021 | 16.30 | 6.54% |
| 2020 | 15.30 | 3.35% |
| 2019 | 14.81 | -11.72% |
| 2018 | 16.77 | -17.96% |
| 2017 | 20.44 | 0.88% |
| 2016 | 20.27 | -4.96% |
| 2015 | 21.32 | -0.27% |
| 2014 | 21.38 | 35.11% |
| 2013 | 15.83 | 17.39% |
| 2012 | 13.48 | -21.01% |
| 2011 | 17.07 | -27.93% |
| 2010 | 23.68 | 11.06% |
| 2009 | 21.32 | -1.85% |
| 2008 | 21.72 | -55.50% |
| 2007 | 48.82 | 80.27% |
| 2006 | 27.08 | 71.28% |
| 2005 | 15.81 | -693.03% |
| 2004 | -2.67 | -128.97% |
| 2003 | 9.20 | -20.97% |
| 2002 | 11.65 | -26.66% |
| 2001 | 15.88 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 23.30 | 84.53% |
DE
|
|
| 26.92 | 113.19% |
DE
|
|
| 55.58 | 340.17% |
JP
|
|
| 61.13 | 384.17% |
CH
|
|
| 34.87 | 176.20% |
IN
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.